Skip to Content

Egrifta (tesamorelin) Disease Interactions

There are 3 disease interactions with Egrifta (tesamorelin):


Tesamorelin (applies to Egrifta) pituitary tumor

Major Potential Hazard, Moderate plausibility. Applicable conditions: Head Injury, Panhypopituitarism

The use of tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma and in patients with active malignancy.


Tesamorelin (applies to Egrifta) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

The use of tesamorelin can result in glucose intolerance. Tesamorelin increases insulin-like growth factor-1 (IGF-1). It is recommended to evaluate glucose status prior to initiation of therapy and to monitor periodically during treatment. Therapy discontinuation may be considered in patients that do not show a clear efficacy response and develop glucose intolerance or diabetes. Diabetes patients should be monitored for potential development or worsening of retinopathy. Care should be exercised when using this agent in patients with diabetes.


Tesamorelin (applies to Egrifta) fluid retention

Moderate Potential Hazard, Moderate plausibility.

The use of tesamorelin may cause fluid retention related to the induction of growth hormone secretion. This manifests as increased tissue turgor and musculoskeletal discomfort resulting in adverse reactions (e.g. edema, arthralgia, and carpal tunnel syndrome) which are either transient or resolve with discontinuation of treatment. Care should be exercised when using tesamorelin in patients at risks for fluid retention.

Egrifta (tesamorelin) drug interactions

There are 45 drug interactions with Egrifta (tesamorelin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.